Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 8, 2026, reports on share repurchase transactions conducted during the first week of June 2026. The company is a global biopharma firm headquartered in London, UK.
Key Financial Metrics and Share Activity
The filing details a non-discretionary share buyback program executed through Citigroup Global Markets Limited. The following table summarizes the daily purchase activity from June 1 to June 5, 2026:
| Date | Shares Purchased | Lowest Price (GBp) | Highest Price (GBp) | VWAP (GBp) |
|---|---|---|---|---|
| 1 June 2026 | 496,356 | 1,832.50 | 1,882.00 | 1,855.38 |
| 2 June 2026 | 337,370 | 1,805.00 | 1,841.00 | 1,824.85 |
| 3 June 2026 | 367,570 | 1,814.50 | 1,856.50 | 1,836.87 |
| 4 June 2026 | 225,000 | 1,863.50 | 1,904.00 | 1,884.74 |
| 5 June 2026 | 217,096 | 1,908.00 | 1,939.00 | 1,922.23 |
Cumulative Activity: Since May 11, 2026, the company has purchased 6,233,812 ordinary shares. The purchased shares are held as Treasury shares.
Capital Structure Post-Purchase:
- Treasury Shares: 267,612,098
- Shares in Issue (excluding Treasury): 4,048,628,915
- Total Voting Rights: 4,048,628,915
- Treasury Voting Rights Percentage: 6.61%
Financial Metrics: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the reduction of outstanding shares and the increase in treasury holdings due to the buyback program. The share price trend during the reporting week showed an upward movement, with the VWAP increasing from 1,855.38 GBp on June 1 to 1,922.23 GBp on June 5.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2025 Annual Report on Form 20-F and the Q1 2026 Results.
Investor Verification Checklist
- Verify the total number of shares in issue (4,048,628,915) for calculating ownership thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the 6.61% voting rights held in treasury to assess potential dilution or buyback impact on earnings per share.
- Review the referenced 2025 Form 20-F and Q1 2026 Results for detailed risk factors and financial performance not included in this 6-K.
- Check the full breakdown of individual purchases via the provided RNS link for granular trading data on the London Stock Exchange and CBOE Europe.